UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025820
Receipt number R000029691
Scientific Title Personalized medication for overactive bladder with imidafenacin treatment
Date of disclosure of the study information 2017/03/15
Last modified on 2019/02/05 12:30:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Personalized medication for overactive bladder with imidafenacin treatment

Acronym

PERMIT study

Scientific Title

Personalized medication for overactive bladder with imidafenacin treatment

Scientific Title:Acronym

PERMIT study

Region

Japan


Condition

Condition

Overactive bladder

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The comparison of impact on the quality of life between personalized and controlled dosage of medicine for overactive bladder

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

King's Health Questionnaire

Key secondary outcomes

Overactive bladder symptom score (OABSS)
IPSS-QOL score
adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

[Personalized medication]
First 2 weeks: imidafenacin 0.1mg x 2/day (Fixed)
Following 3-12 weeks: imidafenacin 0.1-0.4mg/day depending on the subjective decision of the patients

Interventions/Control_2

[Controlled medication]
First 2 weeks: imidafenacin 0.1mg x 2/day (Fixed)
Following 3-12 weeks: imidafenacin 0.2-0.4mg/day depending on the objective decision of the doctors

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

OABSS: urgency score 3 and more, and total score 6 and more

Key exclusion criteria

- Urinary retention within the last 12 months
- Post-void residual urine 100mL and more
- Indwelling catheter or Intermittent catheterization
- Sleep apnea syndrome, Restless legs syndrome or insomnia
- acute urinary infection

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazumasa Torimoto

Organization

Nara Medical University

Division name

Urology

Zip code


Address

840 Shijo-cho, Kashihara, Nara

TEL

0744-22-3051

Email

torimoto@naramed-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kazumasa Torimoto

Organization

Nara Medical University

Division name

Urology

Zip code


Address

840 Shijo-cho, Kashihara, Nara

TEL

0744-22-3051

Homepage URL


Email

torimoto@naramed-u.ac.jp


Sponsor or person

Institute

Nara Medical University

Institute

Department

Personal name



Funding Source

Organization

Nara Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 03 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2017 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2017 Year 03 Month 20 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 01 Month 24 Day

Last modified on

2019 Year 02 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029691


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name